“We are very happy to report this progress in the ADVENT-AML clinical trial,” said Jason B Litten MD, Chief Medical Officer of Chimeric Therapeutics. “The novel combination of CHM 0201 with the standard of care in AML treatment has the potential to transform frontline therapy and enhance outcomes for AML patients.”
And that alone would justify an EV of USD 500m if recent Pharma deals a guide to go by.
Current EV, less than AUD 10m
GLTA
CHM Price at posting:
2.8¢ Sentiment: Buy Disclosure: Held
